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Abstract 
Background: Retinoblastoma is an ocular neoplastic cancer caused primarily due to the mutation/deletion of RB1 
gene. Due to the rarity of the disease very limited information is available on molecular changes in primary retino-
blastoma. High throughput analysis of retinoblastoma transcriptome is available however the proteomic landscape of 
retinoblastoma remains unexplored. In the present study we used high resolution mass spectrometry-based quantita-
tive proteomics to identify proteins associated with pathogenesis of retinoblastoma.
Methods: We used five pooled normal retina and five pooled retinoblastoma tissues to prepare tissue lysates. 
Equivalent amount of proteins from each group was trypsin digested and labeled with iTRAQ tags. The samples were 
analyzed on Orbitrap Velos mass spectrometer. We further validated few of the differentially expressed proteins by 
immunohistochemistry on primary tumors.
Results: We identified and quantified a total of 3587 proteins in retinoblastoma when compared with normal adult 
retina. In total, we identified 899 proteins that were differentially expressed in retinoblastoma with a fold change of 
≥2 of which 402 proteins were upregulated and 497 were down regulated. Insulin growth factor 2 mRNA binding 
protein 1 (IGF2BP1), chromogranin A, fetuin A (ASHG), Rac GTPase-activating protein 1 and midkine that were found 
to be overexpressed in retinoblastoma were further confirmed by immunohistochemistry by staining 15 independent 
retinoblastoma tissue sections. We further verified the effect of IGF2BP1 on cell proliferation and migration capability 
of a retinoblastoma cell line using knockdown studies.
Conclusions: In the present study mass spectrometry-based quantitative proteomic approach was applied to iden-
tify proteins differentially expressed in retinoblastoma tumor. This study identified the mitochondrial dysfunction and 
lipid metabolism pathways as the major pathways to be deregulated in retinoblastoma. Further knockdown studies of 
IGF2BP1 in retinoblastoma cell lines revealed it as a prospective therapeutic target for retinoblastoma.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Retinoblastoma (RB) is an intraocular cancer found in 
children and its incidence is approximately estimated to 
be 1 in 20,000 live births [1] and widely known to affect 
children under 5 years but also rarely reported in adults. 
It occurs due to the inactivation of both alleles of ret-
inoblastoma (RB1) gene located at the 13q14 region of 
chromosome 13 [2, 3]. Abnormality/loss of RB1 gene ini-
tiates retinoma and genomic instability which primarily 
leads to RB [4]. These gene mutations of Rb1 when occur 
in germinal cells results in germinal RB (hereditary) and 
when the mutations are restricted to somatic cells lead to 
sporadic RB (non-hereditary). There are very few protein 
expression profiling studies on RB. In our previous study, 
we compared RB primary tumor with that of control ret-
ina using a two-dimensional (2DE) electrophoresis and 
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mass spectrometry approach. We identified 27 differen-
tially expressed proteins of which 16 were up-regulated 
and 11 were downregulated [5]. We could only probe a 
small number of relatively abundant proteins in our 2DE 
based proteomics approach. The gel free differential pro-
tein expression profiling using iTRAQ based quantitative 
proteomics strategy has emerged as a viable alternative to 
2DE based proteomic approach [6]. This strategy coupled 
with highly sensitive mass spectrometers allows for prot-
eomicprofiling of thousands of proteins in an experiment.
Isobaric tags for relative and absolute quantitation 
(iTRAQ) is a method which labels primary amines in pep-
tides and offers multiplexing capability [7]. The approach 
relies on isobaric tags which upon fragmentation in the 
MS/MS gives rise to unique reporter ions. We used 4-plex 
iTRAQ reagents that yield reporter ions at m/z 114,115,116 
and 117, [8]. Reporter ion intensities provide a measure 
of differential abundance of peptides that can be used to 
deduce differences in protein expression levels across mul-
tiplexed samples. In the present study, we report the first 
comprehensive proteomic signature using high resolution 
LC–MS/MS for comparative screening of RB.
Methods
Sample collection
The present study was conducted at Medical research 
and Vision research foundation, Sankara Nethralaya, 
India and was approved by the institutional ethics board. 
Control retina was collected from C.U. SHAH eye bank, 
Sankara Nethralaya in the age group of 18–28  years 
from the donated eye globes for corneal transplantation 
and were without known concomitant Ocular diseases. 
Tumor tissues were collected with informed consent. 
When the enucleated eye globe was sent for histopatho-
logical examination, a part of the tumor was collected for 
proteomic study and the other part was used for histo-
pathological studies (Additional file 1: Table S1). The col-
lected tumors were snap frozen in liquid nitrogen and 
transferred to −80 °C until used for proteomic analyses.
The tissues were thawed on ice, resuspended in lysis 
buffer (0.5  % SDS buffer) and sonicated on ice for 2–3 
cycles. The samples were centrifuged at 12,000  rpm for 
10  min at 4  °C. The supernatants were collected and 
stored at −80 °C until further use. For proteomic analy-
sis, equal amount of protein from normal retinas (n = 5) 
was pooled and compared with a pooled RB samples 
(n = 5).
iTRAQ labeling
Isobaric tags for relative and absolute quantitation 
(iTRAQ) labeling was performed as per the manufac-
turer’s protocol. Briefly, 100  µg of pooled retina and 
tumor proteins were incubated with reducing agent [tris 
(2-carboxyethyl) phosphine] at 60 °C for 60 min. Methyl-
sulfenylation of cysteine residues was carried out using 
cysteine blocking reagent (methyl methanethiosulfonate) 
for 10  min at room temperature as per manufacturer’s 
protocol. Tryptic digestion was performed overnight 
at 37  °C in sequencing grade trypsin (Promega, San 
Luis Obispo, CA, USA). In order to maintain a techni-
cal replicate, tryptic digests of normal retina was split 
in equal halves and labeled with iTRAQ reagents yield-
ing reporter ions at 114 and 115 m/z. Similarly, tryptic 
digests from RB sample were split in equal halves and 
labeled with iTRAQ reagents yielding reporter ions at 
116 and 117 m/z. All the samples were pooled, vacuum 
dried and stored at −20 °C until further use.
SCX fractionation
The labeled peptides were reconstituted in 1 mL of sol-
vent A [5 mM KH2PO4, 25 % acetonitrile (ACN), pH 2.7] 
and separated using Agilent 1200 series offline HPLC. 
Peptide fractionation was carried out using strong cation 
exchange chromatography. Peptides were eluted using a 
linear gradient of solvent B (350 mM of potassium chlo-
ride in solvent A) at a flow rate of 250 µL/min for 50 min. 
Consecutive fractions with relatively less peptides (based 
on UV absorbance at 280 nm) were pooled and a total of 
18 fractions were prepared for LC–MS/MS analysis. The 
peptides were vacuum dried and reconstituted in 0.1  % 
trifluoroacetic acid (TFA). The samples were desalted 
using C18 zip tips before LC–MS/MS analysis.
LC–MS/MS analysis
LC–MS/MS analysis was carried out on LTQ-Orbitrap 
Velos mass spectrometer (Thermo Scientific, Bremen, 
Germany) interfaced with proxeon Easy nanoLC system. 
The peptide samples were enriched on a trap column 
(75 µm × 2 cm) at a flow rate of 3 µL/min and resolved 
on an analytical column (75 µm × 10 cm) at a flow rate 
of 350 nL/min. These were eluted by using a linear gra-
dient of 7–30 % of solvent B (90 % ACN and 0.1 % for-
mic acid) for 100  min. The MS analysis was performed 
on Orbitrap mass analyzer in a data dependent manner 
with full scans acquired at a mass resolution of 60,000 
at 400 m/z. 20 most intense precursor ions were chosen 
for fragmentation in each cycle. MS/MS fragmentation 
was carried out using high energy collision dissociation 
with 41 % normalized collision energy at a mass resolu-
tion of 15,000 at 400 m/z. The isolation window was set 
to 2 m/z. The precursor ions that were fragmented were 
dynamically excluded for 45  s. Full scans were acquired 
with AGC target value of 100,000 and for FT MS/MS it 
was set at 50,000 and maximum accumulation time was 
300 and 200 ms, respectively. The lock mass was enabled 
for accurate mass measurement.
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Protein identification and quantitation
The obtained MS data was analyzed using Proteome 
Discoverer (version 1.3). The peptide search work flow 
includes spectrum selector followed by reporter ion 
quantitation (Fig.  1). The spectra were searched using 
MASCOT and SEQUEST search algorithm against NCBI 
RefSeq database version 65 containing 34,454 proteins. 
The search parameters included trypsin as the enzyme 
with one missed cleavage allowed, methylsulfenylation of 
cysteine, iTRAQ modifications at N-terminus of peptide 
and lysine as static modifications. Oxidation of methio-
nine was set as dynamic modification. Precursor and 
fragment mass tolerance was set at 20 ppm and 0.1 Da, 
respectively. The protein and peptide data were extracted 
using high peptide confidence and top one peptide rank 
filters. The false discovery rate (FDR) was calculated by 
searching the peptide sequences against a decoy database 
and cut off of <1 % was used for identified peptides.
Bioinformatic analysis
Bioinformatic analysis and annotations of the obtained 
protein list was carried out based on their localiza-
tion, biological process and molecular function as per 
human protein reference database (HPRD) [9], which is 
in compliance with the gene ontology standards. Pathway 
analysis was performed by ingenuity pathway analysis 
(Ingenuity Systems, Redwood City, CA, USA).
Immunohistochemistry
A select set of differentially expressed proteins in RB were 
validated in individual tumor tissues (n = 15). Immuno-
histochemical labeling (IHC) of CHGA, AHSG, IGF2BP1 
RACGAP1 and MDK was performed on paraffin wax 
embedded tumor sections. Deparaffinization and antigen 
retrieval was followed as described previously [5]. The 
antibodies and their dilutions are as follows: anti-CHGA 
polyclonal antibody at 1:25, polyclonal antibody at 1:10, 
anti-AHSG polyclonal antibody at 1:25, anti-RACGAP1 
polyclonal antibody at 1:25 anti-IGF2BP1 polyclonal 
antibody at 1:25, anti-MDK polyclonal antibody at 1:150 
for IHC applications. All the antibodies were purchased 
from Pierce antibodies and raised in rabbit against 
human proteins. Staining for all the five proteins were 
observed with anti-rabbit IgG-Poly-HRP using the Novo-
Link Max Polymer (Leica biosystems, Germany) detec-
tion system according to the manufacturer’s protocol. 
The protein expression was calculated and the tumors 
were grouped into Group I (1–33 %), Group II (34–67 %), 
Group III (68–100 %) based on their staining intensities. 
The intensity was given ‘–’ as negative, rank ‘±’ for dull 
and rank ‘+’ for intense staining. Overall distribution and 
staining pattern of the tissues was ranked from 0 to 6 that 
were obtained by multiplying the group and the staining 
intensity. The staining intensities were ranked one for 
negative, ranked two for dull and ranked three for intense 
staining (Additional file 1: Table S2).
Cell culture
RB cell line Y79 was obtained from Riken Bio Resource 
center (Japan). Y79 cells were cultured in ATCC modified 
RPMI 1640 (Invitrogen, USA) media containing sodium 
pyruvate supplemented with 10  % fetal bovine serum 
Fig. 1 Schematic representation of work flow for the sample prepa-
ration and data analysis of total proteome
Page 4 of 13Danda et al. Clin Proteom  (2016) 13:29 
(FBS) (Invitrogen, USA) at 37 °C in 5 % CO2 humidified 
incubator.
mRNA knockdown studies
For evaluating the role of IGF2BP1 over expressed protein 
in tumor progression, siRNA based knock down study of 
IGF2BP1 protein was performed in Y79 RB cell line. The 
siRNA was delivered into the cells using Lipofectamine 
2000 (Invitrogen, USA) according to the manufacturer’s 
protocol. The IGF2BP1 siRNA (5′ CCGGGAGCAGACC 
AGGCAA3′) was obtained from Dharmacon, Thermo 
Scientific, Pittsburg, PA, USA. Transfections were per-
formed in 50  pm/µL of IGF2BP1 siRNA and scrambled 
siRNA. The cells were seeded 24  h prior to the experi-
ment and were incubated for 48 h post transfection. The 
cells were collected at 3000 rpm for 10 min at 4 °C. The 
collected cells were used for the downstream processes 
involving western blot and real-time PCR.
Real‑time PCR
Total RNA was isolated using Trizol reagent (Invitrogen, 
USA). cDNA synthesis was carried out using high capac-
ity reverse transcriptase kit (Applied Biosystems, USA) as 
per the manufacturer’s protocol. Ct values for the target 
genes were calculated and normalized against GAPDH 
housekeeping gene. The primers used for the real-time 
PCR were IGF2BP1 FP 5′ TAGTACCAAGAGACCAG 
ACCC 3′ RP 5′ GATTTCTGCCCGTTGTTGTC 3′ 
GAPDH FP 5′ GCCAAGGTCATCCATGACAAC 3′ 
RP 5′ GTCCACCACCCTGTTGCTGTA 3′. The fold 
changes of the genes were expressed in the log2 relative 
units. The PCR products were detected using ABI PRISM 
7500 detection system and analysis was done on ABI 
PRISM 7500 SDS software (Applied Biosystems, USA).
Western blot analysis
For western blot analysis, the IGF2BP1siRNA was trans-
fected into Y79 as previously described. The cells were 
collected and washed twice with PBS. The washed cells 
were re-suspended in RIPA buffer (R 0278, Sigma, USA). 
The lysed cells were spun at 12,000 rpm for 5 min at 4 °C. 
Protein estimation was carried out using BCA reagent 
(Thermo Scientific, USA) as per the manufacturer’s pro-
tocol. Equal amount of protein (50 µg) was resolved using 
polyacrylamide gel electrophoresis and transferred on 
to a nitrocellulose membrane. The membrane was incu-
bated with IGF2BP1 primary antibody at 4 °C overnight. 
The membrane was washed and probed with mouse 
anti-rabbit (Sigma Aldrich, USA) secondary antibody 
for 2 h at room temperature. After the incubation time, 
the membrane was developed with TMB H2O2 (Banga-
lore Genei, India), scanned and documented. The mem-
brane was stripped with stripping solution and re-probed 
with β-actin primary antibody (Sigma Aldrich, USA). The 
membrane was washed twice with PBS and probed with 
rabbit anti-mouse (Sigma Aldrich, USA) secondary anti-
body for 2  h. The membrane was developed with TMB 
H2O2, scanned and documented.
Proliferation assay
3-(4,5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay was performed to evaluate the per-
centage of viable cells in the siRNA treated cells. Briefly, 
the cells were transfected with the siRNA and incubated 
for 48 h. Post incubation, the cells were replaced with 10 % 
of MTT in serum containing media and incubated for 4 h 
at 37 °C. The formazan crystals were confirmed, dissolved 
in DMSO and absorbance was read at 570 nm using Spec-
tramax M5 spectrophotometer (Molecular devices, USA). 
Data was expressed as mean ± SD of 3 independent exper-
iments and each experiment was done in triplicates.
Wound healing assay
To evaluate the migration of Y79 cells, wound healing assay 
was performed. The cells were seeded 1  day prior to the 
treatment with siRNA in a poly-l-lysine coated plate. The 
cells were transfected with siRNA and a wound was created 
with a tip. The cells were documented at 0 h and incubated 
for 24 h and again documented to assess the migration of 
cells using Axio Vision phase contrast microscope.
Data availability
The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium [10] via 
the PRIDE partner repository with the dataset identifier 
PXD002774.
Results and discussion
We have analyzed the total proteome of RB isolated from 
the pooled clinical samples which reduces the individ-
ual tumor variation and leads to increase in confidence 
of target molecule identification. The clinicopathologi-
cal features of the tumours used in the proteomic study 
include samples below 4 years (Additional file  1: Table 
S1).  We performed iTRAQ labeling and LC–MS/MS to 
generate the differentially expressed proteins. We identi-
fied 3671 and quantified 3587 proteins, out of which, 899 
proteins were differentially expressed with a fold change 
of ≥2 (Additional file 2). These 899 (402 up-regulated and 
497 down-regulated) differentially expressed proteins 
were taken for further analysis. Differentially expressed 
proteins include spleen tyrosine kinase (SYK), stathmin1 
(STMN1) and vimentin (VIM) that have been previously 
reported to be overexpressed in RB [5, 11]. In addition, 
we identified several novel proteins and validated CHGA, 
AHSG IGF2BP1 and RACGAP1 that were previously 
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unreported in RB by IHC. Representative MS/MS spectra 
of differentially expressed proteins are shown in Figs. 2, 3.
Overlap of proteomic data with previously published 
datasets
The observed 899 differential proteins were compared 
with published transcriptome dataset [12]. We observed 
that 175 proteins were overlapped with the published 
transcriptome profile. The overlapped dataset (Fig.  4) 
showed 100 proteins were up-regulated and 73 proteins 
were down-regulated which indicates that these proteins 
are transcriptionally regulated.
Previously reported up‑regulated proteins
We then examined the presence of overexpressed pro-
teins reported previously in RB. Cellular retinoic acid 
binding protein 2 (CRABP2) is a cytoplasmic protein, 
which translocates to nucleus upon ligand binding. 
CRABP2 is involved in cell proliferative activity by acti-
vating PPARβ/δ and FABP5 proteins [13]. In our data, we 
observed that FABP5 was not up-regulated suggesting 
an alternative mechanism for the activation and overex-
pression of CRABP2 in RB tumors. CRABP2 is known 
to be overexpressed in variety of cancers such as breast 
and ovarian cancers [14, 15]. The siRNA based knock-
down study of CRABP2 in head and neck squamous cell 
carcinoma showed decrease in tumour cell invasion [16]. 
Kinesin like protein 11 (KIF11) belongs to family of pro-
tein Kinesins and are classified into 14 subfamilies (1–14) 
based on their phylogenetic analysis of motor domain. 
It is involved in cell division and intracellular vesicle 
and organelle transport. In one of the earlier studies on 
mRNA profiling of RB it was found to be 15-fold upregu-
lated [12]. In our present quantitative proteomic profil-
ing, KIF11 was threefold upregulated (Additional file  2). 
Knockdown studies of KIF11 by RNAi and antibodies 
showed activation of mitotic arrest, inhibition of spindle 
formation and apoptosis in the tumor cells [17]. SYK, is a 
72 kDa protein localized to cytoplasm. It is a non-receptor 
kinase involved in signal transduction and plays an impor-
tant role in regulation of immunomodulatory signaling 
and involved in several hematopoietic malignancies. In an 
earlier study by Zhang et al. [11], overexpression of SYK 
in RB was involved in cell survival. Knockdown studies by 
shRNA and small molecule inhibitor revealed that SYK 
inhibition leads to increased apoptosis in RB cell lines and 
orthotopic xenografts models respectively. In concord-
ance with the earlier study a 12-fold upregulation of SYK 
was observed in our present dataset.
Bioinformatics analysis
Sub-cellular classification of the differentially expressed 
proteins was done using HPRD [9] (Fig. 4). In our present 
study, of the 899 differentially expressed proteins, 187 are 
localized in cytoplasm, 162 in plasma membrane, 128 in 
the nucleus, 104 proteins are putative extracellular pro-
teins and 160 are localized to other organelles. A few 
differential proteins do not have the localization informa-
tion in the literature.
Pathway analysis
In order to understand the biological significance of these 
molecules, we analyzed these proteins using Ingenuity 
pathway knowledge base and identified the Canonical 
pathways, networks, molecular and cellular processes, 
diseases and disorders that are relevant to the dataset. 
The top five canonical pathways identified include mito-
chondrial dysfunction, LXR/RXR activation, acute phase 
response signaling, complement system and photo trans-
duction pathway. Neurological diseases, skeletal and 
muscular disorders, cancer, hereditary disorders and 
physiological disorders were major diseases and disor-
ders identified. The top molecular and cellular processes 
identified include lipid metabolism, molecular transport, 
small molecule biochemistry, nucleic acid metabolism, 
DNA replication, recombination and repair. Lipid metab-
olism and mitochondrial dysfunction are the top most 
deregulated pathways. In many cancers, lipid synthesis 
is key metabolic process upregulated for cancer progres-
sion and metastasis. Increase in the concentration of 
lipids leads to the formation of lipid droplets which are 
required for the membranes synthesis, cellular metabo-
lism and energy production [18]. Mitochondrial dysfunc-
tion in the present study included down regulation of 
proteins from Complex I, Complex III, Complex IV and 
Complex V which are responsible for the generation of 
energy in the cell. Complex I (CI) is the first component 
that regulates the production of reactive oxygen species 
(ROS) and ATP generation [19]. In the absence/defec-
tive CI there is a reduction in the ATP generation which 
effects the cell survival, which could be compensated by 
increase in the lipid synthesis and metabolism as energy 
source in RB.
Validation of novel proteins identified in retinoblastoma 
by immunohistochemistry
In the present study, we identified 559 novel proteins 
with no previous report of differential expression in RB 
compared to retina. A partial list of novel proteins iden-
tified and their corresponding fold change are given in 
Table  1. Some of the proteins identified in our dataset 
were further evaluated by IHC (Fig. 5; Table 1). The pro-
teins selected for IHC validation were based on magni-
tude of overexpression and novelty in the context of RB, 
involvement of proteins in tumor progression. CHGA, 
AHSG, RACGAP1, IGF2BP1 and MDK were selected 
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Fig. 2 MS/MS spectra of the peptides with their reporter ions for the over expressed proteins in retinoblastoma. Relative intensities of reporter ions 
for a IGF2BP1 and b CHGA
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Fig. 3 MS/MS spectra of the peptides with their reporter ions for the over expressed proteins in retinoblastoma. Relative intensities of reporter ions 
for a AHSG and b MDK
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for validation studies on formalin fixed paraffin embed-
ded tissue sections. These proteins were overexpressed 
more than twofold compared to non-neoplastic retina. 
The staining intensity and distribution is summarized in 
Table  2. Fifteen tumors and three normal retinas were 
taken for IHC analysis. All 15 tumors showed positiv-
ity for all the antibodies. Nearly 50 % of tumor sections 
showed strong staining for CHGA and the remaining 
tumors showed moderate staining. 90  % of the tumor 
sections showed strong staining for AHSG, RACGAP1, 
IGF2BP1 and MDK the remaining tumors showed mod-
erate staining with the antibodies. All the non-neoplastic 
retinas showed no staining for these proteins using the 
same antibodies (Additional file 1: Table S2).   
CHGA
Chromogranin A is a glycoprotein of 439 amino acids 
and belongs to the family of secretogranin [20]. It is an 
extracellular matrix protein released with co-hormones 
from the neuroendocrine cells into the extracellular envi-
ronment and then into circulation [21]. CHGA is the pre-
cursor molecule for many of the bioactive peptides like 
vasostatin I and II, chromacin, pancreastatin, parasta-
tin, catestatin and WE-14 [22]. It inhibits the VEGF and 
thrombin induced endothelial cell permeability [23] and 
helps in controlling the angiogenesis and vascular leak-
age by inhibiting the TNFα elicited effect on endothelial 
cells. High expression of CHGA in RB might be involved 
in causing increased cell proliferation, migration and 
motility leading to tumor formation and increased angi-
ogenesis for tumor growth. High expression of CHGA 
was observed in small cell lung cancer, neuroendocrine 
tumors, medullary carcinoma of thyroid and in neuro-
blastoma [24].
AHSG
Alpha-HS-glycoprotein also called as fetuin-A, is a serum 
glycoprotein synthesized and secreted by brain, kidneys 
and liver into serum [25]. However presence of the pro-
tein is identified in pancreatic ductal adenocarcinoma 
and hepatocellular carcinoma tissues [26, 27]. AHSG is 
a 51–67  kDa and belongs to cystatin family of proteins 
lacking protease-inhibitory capacity [28, 29]. It regu-
lates and activates the PI3- kinase/AKT pathway, which 
is a downstream signaling molecule of TGFβ resulting in 
impaired tumor growth [30]. In one study on breast can-
cer, AHSG enhanced the formation of exosome, which 
helped in the cell adhesion in the metastatic cancer cells 
[31]. The cell adhesion in the presence of AHSG is medi-
ated by annexins [32].
MDK
Midkine is a heparin binding growth factor involved in 
cell migration and proliferation. It is a 143 amino acid 
protein which includes secretory signal peptides yield-
ing 13 kDa mature peptides [33]. The C-terminal domain 
of MDK consists of two clusters composed of lysine and 
arginine residues that are involved in the heparin bind-
ing activity [34]. The cell surface receptors for MDK 
includes ALK, LRP1, integrin, PTPζ, notch2, glypican2, 
neuroglycan of which glypican2 was found to be twofold 
upregulated in our study. MDK mediates cell prolifera-
tion by activating MEK1/2 and PI3K signaling pathways. 
In tumor cell lines, inhibition of apoptosis and mitogenic 
function mediated by MDK induced phosphorylation of 
MAP kinases, extracellular signal regulated kinases and 
PI3 kinases. In our present study, MDK showed a 9.5-fold 
change. This was further confirmed by IHC where we 
observed high staining intensity for MDK (Table 2). This 
protein is found to be overexpressed in many cancers 
such as oral, brain and cervical [35, 36].
IGF2BP1
The insulin-like growth factor-2 mRNA-binding pro-
tein 1 is a 58–66 kDa protein that belongs to highly con-
served RNA binding protein family (RBP family). The 
Fig. 4 a Sub-cellular classification of differentially regulated proteins 
in Retinoblastoma based on annotations from human proteome 
reference database. b Comparison of deregulated proteins involved 
in present study with previously reported transcriptome data of 
retinoblastoma. A total of 175 proteins showed positive correlation 
with the transcriptome
Page 9 of 13Danda et al. Clin Proteom  (2016) 13:29 
RBP family consists of IGF2BP1, IGF2BP2 IGF2BP3 
which shows 56 % amino acid identity and high similar-
ity within the protein domains. IGF2BP1 and IGF2BP3 
show a higher identity of 73  % with each other. These 
RNA binding proteins (RBPs) consists of two RNA-rec-
ognition motifs (RRMs) in the N-terminal region and 
four hnRNP-K homology (KH) domains in the C-termi-
nal region [37]. These are localized to cytoplasm with 
granular in appearance and alternatively these are also 
localized to nucleus. IGF2BP1 showed higher expression 
in embryo and lower expression levels in adult organs 
with exceptions in reproductive organs [37]. IGF2BP1 
transcriptional expression was negatively regulated by 
CTNNB1 and positively regulated by MYC [38]. In our 
study, negative feedback could be active as CTNNB1 is 
found to be twofold down regulated and IGF2BP1 was 
14-fold up regulated whereas c-MYC remained unal-
tered. In one study it was shown that IGF2BP1 binds to 




Protein Peptides Fold change
Tumor/normal
HIST1H1B Histone H1.5 6 16.9
CHGA Chromogranin-A 4 15.6
IGF2BP1 Insulin-like growth factor 2 
mRNA-binding protein 1
2 13.1
KRT17 Keratin, type I  
cytoskeletal 17
9 12.8
KRT16 Keratin, type I  
cytoskeletal 16
17 12.8





RACGAP1 Rac GTPase-activating 
protein 1
1 12.3
SYK Tyrosine-protein kinase 
SYK isoform Syk(S)
2 12.1
KRT6C Keratin, type II cytoskel-
etal 6C
18 11.6





APOA2 Apolipoprotein A-II 3 10.9
DDX49 Probable ATP-dependent 
RNA helicase DDX49
1 10.6
LAMA3 Laminin subunit alpha-3 1 10.4
IGFALS Insulin-like growth factor-
binding protein complex 
acid labile subunit
1 10.2
HMGA2 High mobility group pro-
tein HMGI-C isoform a
2 10.1
MCM4 DNA replication licensing 
factor MCM4
16 10.0
KPNA2 Importin subunit alpha-1 2 9.4
DDB2 DNA damage-binding 
protein 2
1 9.4
IGF2BP3 Insulin-like growth factor 2 
mRNA-binding protein 3
7 9.3
MDK Midkine isoform b 1 9.0




MCM6 DNA replication licensing 
factor MCM6
15 8.3
Fig. 5 Immunohistochemistry of selected proteins IGF2BP1, RAC-
GAP1, CHGA, MDK and ASHG in retinoblastoma primary tumors and 
non-neoplastic control retina
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MYC mRNA and inhibits its degradation in vitro but it 
was not observed in  vivo [39]. Immunohistochemical 
staining pattern showed high expression of IGF2BP1 in 
cytoplasm in all RB tumors.
RACGAP1
Rac gap activating protein (RACGAP1) is a 63  kDa 
protein involved in the spindle fibre complex by inter-
acting with KIF23 which are essential for cytokine-
sis [40] and also in the invasion/migration of cancer 
cells [41]. It is involved in the invasion/migration by 
activating PKB/AKT pathway. In an earlier study it 
was found that RACGAP1 knockdown resulted in 
reduction of cancer cell migration [42]. Ras GTPase 
activating like protein 1 (IQGAP 1) is a scaffolding 
protein with multiple protein interacting domains. It is 
involved in many functions such as cell–cell adhesion, 
cell polarization and directional migration. Recent 
studies showed that it interacts with phosphorylated 
RACGAP1 to form a complex and suppresses Rac and 
activates Rho A, stimulating cell invasion/migration. 
Knockdown studies of IQGAP1 showed reduction in 
invasion/migration in ovarian cancer cell lines [42]. 
We observed both the proteins were upregulated in 
our study, which could be the reason for the invasive-
ness of the RB tumor.
Functional validation of overexpressed proteins
To understand the involvement of the over-expressed 
proteins in cell proliferation, we performed functional 
knockdown of IGF2BP1 protein which is over-expressed 
in our study. Knockdown studies of the IGF2BP1 were 
performed by siRNA based RNA interference studies in 
Y79 RB cell lines. As we did not observe a significant dif-
ference of IGF2BP1 mRNA and protein levels between 
untreated and scrambled siRNA treated cells (data 
not shown), knockdown of IGF2BP1 studies were car-
ried out with untreated Y79 cells as control. A 4.5-fold 
reduction in mRNA was observed in siRNA treated 
cells (Fig.  6a). Western blot analysis revealed reduced 
protein expression in treated when compared to con-
trol cells (Fig. 6b). We evaluated the role of this protein 
in cell proliferation/migration. Cell viability by MTT 
assay showed reduction in cell proliferation by 30–40 % 
in siRNA treated Y79 cells compared to untreated Y79 
cells (Fig.  6c). Wound healing assay showed decreased 
cell migration in the cells treated with siRNA when 
compared to untreated Y79 cells at 48 h (Fig. 6d). These 
results indicate that reduction in the expression of 
IGF2BP1 leads to decreased proliferation and cell migra-
tion of RB cells indicating a novel potential therapeutic 
target. In hepatocellular carcinoma, stable knockdown 
of IGF2BP1 showed reduction in tumor migration and 
induction of apoptosis [43]. Overexpression of IGF2BP1 
in rhabdomyosarcoma induced drug resistance [44]. The 
mechanism of cell proliferation and anti-apoptotic effect 
of IGF2BP1in RB needs further elucidation.
Conclusions
This is the first comprehensive report of proteomic pro-
file of RB tumor. The proteomic profile offered insights 
into proteins involved in tumor proliferation which 
were not reported previously. Functional validation of 
IGF2BP1 demonstrated its role in cancer cell prolifera-
tion/migration and offers a putative novel therapeutic 
target molecule for RB.
Table 2 Immunohistochemistry scoring of  15 tumors and  three control retina the details of  scoring is described in   
“Methods” section
Protein Proteomic data Sample No of cases  
showing expression
Staining intensity
0 (−) 1 (±) 2 (+)
CHGA Up-regulated Case 15/15 9 6
Control 3 0
AHSG Up-regulated Case 15/15 3 12
Control 3 0
RACGAP1 Up-regulated Case 15/15 2 13
Control 3 0
MDK Up-regulated Case 15/15 3 12
Control 3 0
IGF2BP1 Up-regulated Case 15/15 3 12
Control 3 0
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